Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Aug 18;15(2):e1846. doi: 10.1002/wnan.1846

FIGURE 2.

FIGURE 2

Proposed model of paclitaxel pharmacokinetics, assuming pharmacokinetically distinguishable forms of paclitaxel in the blood compartment; Pharmacokinetically distinguishable forms: Unbound (CUnbound), bound to plasma protein (CBound), in micellar form together with CrEL (CMicellar), and bound to or distributed into red blood cells (Crbc). Further, C was assumed to be in equilibrium with tissues (Double-headed arrows denote processes with assumed instantaneous equilibrium. The star indicates a nonlinear process; van Zuylen et al., 2001)